The Stomatognathic System as an Expanding Frontier for Botulinum Toxin Therapy
Toxins · 2026
DOI: 10.3390/toxins18100428 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Toxins, 2026. Verfasst von Kazuya Yoshida. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, National Hospital Organization, Kyoto Medical Center, 1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto 61…. Hauptthemen laut MEDLINE: Botulinum Toxins, Stomatognathic System, Neuromuscular Agents, Stomatognathic Diseases. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, JSPS.
Abstract (Originalsprache)
Botulinum neurotoxin (BoNT) therapy has expanded from focal chemodenervation to a versatile therapeutic modality used across multiple medical specialties. The stomatognathic system is particularly suited to BoNT therapy because motor, sensory, articular, secretory, and aesthetic functions converge within a compact anatomical region. Current and emerging applications include oromandibular dystonia, dyskinesia, bruxism, tremor, hemimasticatory spasm, embouchure dystonia, masticatory muscle and temporomandibular disorder-related pain, trigeminal neuralgia, recurrent temporomandibular joint dislocation, sialorrhea, Frey syndrome, masseter prominence, gummy smile, and perioral wrinkles. Evidence and regulatory status vary substantially among indications, and many applications remain off-label. Dentistry and oral and maxillofacial surgery have historically played a limited role in BoNT therapy despite their detailed anatomical and functional expertise in this region. However, interest is increasing, and the recent approval of onabotulinumtoxinA in Japan for masseter prominence in adults younger than 65 years represents an important milestone. This review synthesizes current applications, limitations, safety considerations, and future directions, and proposes the stomatognathic system as a major expanding frontier for BoNT therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, National Hospital Organization, Kyoto Medical Center, 1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto 612-8555, Japan.
ORCID-Profile: Kazuya Yoshida
Förderung
- Japan Society for the Promotion of Science
- JSPS
Zitieren
APA
Yoshida, K. (2026). The Stomatognathic System as an Expanding Frontier for Botulinum Toxin Therapy. Toxins. https://doi.org/10.3390/toxins18100428
Vancouver
Yoshida K. The Stomatognathic System as an Expanding Frontier for Botulinum Toxin Therapy. Toxins. 2026. doi:10.3390/toxins18100428
BibTeX
@article{Yoshida2026,
author = {Yoshida, Kazuya},
title = {The Stomatognathic System as an Expanding Frontier for Botulinum Toxin Therapy},
journal = {Toxins},
year = {2026},
doi = {10.3390/toxins18100428}
}
EUVIMED